中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2009年
12期
1266-1268
,共3页
甘精胰岛素%二甲双胍%2型糖尿病%糖代谢%C-反应蛋白%肿瘤坏死因子α%白细胞介素-6
甘精胰島素%二甲雙胍%2型糖尿病%糖代謝%C-反應蛋白%腫瘤壞死因子α%白細胞介素-6
감정이도소%이갑쌍고%2형당뇨병%당대사%C-반응단백%종류배사인자α%백세포개소-6
Insulin glargine%Mefformin%Type 2 diabetes mellitus%Glucose metabolism%C-reactive protein%TNF-α%IL-6
目的 观察甘精胰岛素与二甲双胍联合治疗对初诊2型糖尿病(T2DM)患者炎症因子的影响.方法 对110例新诊断的T2DM患者进行甘精胰岛素(起始剂量10 U/d)与二甲双胍(0.5 g,每天3次)联合治疗(T2DM组),疗程12周.另入选100例同期进行健康体检的正常人群为正常对照组.观察2组研究对象基线血糖指标空腹血糖(FPG)、餐后2 h血糖(2 hPG)和糖化血红蛋白(HbA_1c)以及炎症因子C-反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)和白细胞介素-6(IL-6)的差异,并比较T2DM组治疗前后血糖指标和炎症因子的变化.结果 观察前T2DM组的血糖指标及炎症因子明显高于对照组(P均＜0.05),其他基础临床资料没有差异(P均＞0.05).经甘精胰岛素和二甲双胍联合治疗12周后,T2DM组的血糖指标明显改善,FPG:治疗前(14.8±3.9)mmoL/L,治疗后(6.6±2.1)mmol/L;2 hPG:治疗前(17.6±3.3)mmol/L,治疗后(8.3±1.2)mmoL/L;HbA1c:治疗前(9.6±2.7)%,治疗后(6.5±0.8)%(t值分别为7.40、8.37、3.98,P均＜0.01).炎症因子水平也显著下降,CRP:治疗前(8.8±2.5)mg/L,治疗后(5.5±1.4)mg/L;TNF-α:治疗前(2.9±0.6)ng/L,治疗后(1.6±0.2)ng/L;IL-6:治疗前(170.3±22.2)pg/L,治疗后(105.9±14.6)pg/L(t值分别为4.61、3.52、5.68,P均＜0.05).结论 甘精胰岛素与二甲双胍联合治疗可以改善初诊T2DM患者的糖代谢,降低患者炎症因子的水平.
目的 觀察甘精胰島素與二甲雙胍聯閤治療對初診2型糖尿病(T2DM)患者炎癥因子的影響.方法 對110例新診斷的T2DM患者進行甘精胰島素(起始劑量10 U/d)與二甲雙胍(0.5 g,每天3次)聯閤治療(T2DM組),療程12週.另入選100例同期進行健康體檢的正常人群為正常對照組.觀察2組研究對象基線血糖指標空腹血糖(FPG)、餐後2 h血糖(2 hPG)和糖化血紅蛋白(HbA_1c)以及炎癥因子C-反應蛋白(CRP)、腫瘤壞死因子α(TNF-α)和白細胞介素-6(IL-6)的差異,併比較T2DM組治療前後血糖指標和炎癥因子的變化.結果 觀察前T2DM組的血糖指標及炎癥因子明顯高于對照組(P均＜0.05),其他基礎臨床資料沒有差異(P均＞0.05).經甘精胰島素和二甲雙胍聯閤治療12週後,T2DM組的血糖指標明顯改善,FPG:治療前(14.8±3.9)mmoL/L,治療後(6.6±2.1)mmol/L;2 hPG:治療前(17.6±3.3)mmol/L,治療後(8.3±1.2)mmoL/L;HbA1c:治療前(9.6±2.7)%,治療後(6.5±0.8)%(t值分彆為7.40、8.37、3.98,P均＜0.01).炎癥因子水平也顯著下降,CRP:治療前(8.8±2.5)mg/L,治療後(5.5±1.4)mg/L;TNF-α:治療前(2.9±0.6)ng/L,治療後(1.6±0.2)ng/L;IL-6:治療前(170.3±22.2)pg/L,治療後(105.9±14.6)pg/L(t值分彆為4.61、3.52、5.68,P均＜0.05).結論 甘精胰島素與二甲雙胍聯閤治療可以改善初診T2DM患者的糖代謝,降低患者炎癥因子的水平.
목적 관찰감정이도소여이갑쌍고연합치료대초진2형당뇨병(T2DM)환자염증인자적영향.방법 대110례신진단적T2DM환자진행감정이도소(기시제량10 U/d)여이갑쌍고(0.5 g,매천3차)연합치료(T2DM조),료정12주.령입선100례동기진행건강체검적정상인군위정상대조조.관찰2조연구대상기선혈당지표공복혈당(FPG)、찬후2 h혈당(2 hPG)화당화혈홍단백(HbA_1c)이급염증인자C-반응단백(CRP)、종류배사인자α(TNF-α)화백세포개소-6(IL-6)적차이,병비교T2DM조치료전후혈당지표화염증인자적변화.결과 관찰전T2DM조적혈당지표급염증인자명현고우대조조(P균＜0.05),기타기출림상자료몰유차이(P균＞0.05).경감정이도소화이갑쌍고연합치료12주후,T2DM조적혈당지표명현개선,FPG:치료전(14.8±3.9)mmoL/L,치료후(6.6±2.1)mmol/L;2 hPG:치료전(17.6±3.3)mmol/L,치료후(8.3±1.2)mmoL/L;HbA1c:치료전(9.6±2.7)%,치료후(6.5±0.8)%(t치분별위7.40、8.37、3.98,P균＜0.01).염증인자수평야현저하강,CRP:치료전(8.8±2.5)mg/L,치료후(5.5±1.4)mg/L;TNF-α:치료전(2.9±0.6)ng/L,치료후(1.6±0.2)ng/L;IL-6:치료전(170.3±22.2)pg/L,치료후(105.9±14.6)pg/L(t치분별위4.61、3.52、5.68,P균＜0.05).결론 감정이도소여이갑쌍고연합치료가이개선초진T2DM환자적당대사,강저환자염증인자적수평.
Objective To observe the effect of insulin glargine plus mefformin on inflammatory factors(IF) in the treatment of patients with newly diagnosed type 2 diabetes(T2DM).Methods 110 patients with newly diagnosed T2DM were given insulin glargine(beginning dose:10 U/d) and mefformin(0.5 g,tid) for 12 weeks;while 100 cases selected for the same period from the normal healthy population were taken as control group.Baseline fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin (HbA_1c),C-reactive protein(CRP),TNF-α and IL-6 were observed.Results Before treatment,FPG,2 hPG,HbA_1c and IF in T2DM group were obviously higher than those in control group(P＜0.05),but there was no difference in other clinical data (P＞0.05).After 12 weeks treatment,in T2DM group there was a significant improvement in blood glucose targets [FPG from (14.8±3.9) mmol/L to (6.6±2.1) mmoL/L;2 hPG from (17.6±3.3) mmol/L to (8.3±1.2)mmol/L;HbA1c from (9.6±2.7)% to (6.5±0.8)%,t=7.40,8.37,3.98,P＜0.05],and the level of IF also decreased significantly [CRP from (8.8±2.5) mg/L to (5.5±1.4) mg/L;TNFα from (2.9±0.6) ng/L to (1.6±0.2) ng/L;IL-6 from(170.3±22.2) pg/L to (105.9±14.6) pg/L,t=4.61,3.52,5.68,P＜0.05].Conclusions Insulin glargine and mefformin combined therapy can improve glucose metabolism in patients with newly diagnosed T2DM,and decrease the levels of IF.
